Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706497 | 0.88 | OPRL1 (0.54) | SIGMAR1TSHRALDH1A1MEN1POLB | |
| SCHEMBL7701290 | 0.87 | LMNA (0.50) | SIGMAR1CYP2D6ALDH1A1MAPTMAPK1 | |
| SCHEMBL7706380 | 0.86 | DRD4 (0.50) | SIGMAR1ALDH1A1MAPTHSD17B10DRD2 | |
| SCHEMBL5556020 | 0.85 | DRD2 (0.47) | SIGMAR1CYP2D6ALDH1A1LMNAMEN1 | |
| SCHEMBL16876781 | 0.85 | OPRL1 (0.46) | SIGMAR1CYP2D6TSHRMAPK1HSD17B10 | |
| SCHEMBL16876782 | 0.85 | CHRNA7 (0.47) | SIGMAR1CYP2D6ALDH1A1MAPTMAPK1 | |
| SCHEMBL21634309 | 0.84 | CCR5 (0.45) | CYP2D6ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL7703855 | 0.80 | MCHR1 (0.47) | SIGMAR1ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL16876863 | 0.80 | OPRL1 (0.44) | SIGMAR1CYP2D6MAPK1POLBHSD17B10 | |
| SCHEMBL16876851 | 0.80 | RORC (0.42) | CYP2D6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829579-B1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S P A (IT) | 2023-08-02 | — | — | EP | claimed |
| EP-3829579-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | Maria Cecilia Hospital S.p.A. (IT) | 2021-06-09 | — | — | EP | claimed |
| WO-2020021378-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S.P.A. (IT) | 2020-01-30 | — | — | WO | claimed |
| EP-3829579-B1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S P A (IT) | 2023-08-02 | — | — | EP | disclosed |
| EP-3829579-B1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S P A (IT) | 2023-08-02 | — | — | EP | disclosed |
| EP-3829579-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | Maria Cecilia Hospital S.p.A. (IT) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020021378-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S.P.A. (IT) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020021378-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S.P.A. (IT) | 2020-01-30 | — | — | WO | disclosed |
| US-5610142-A | Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids | SCIOS INC. (US) | 1997-03-11 | — | — | US | disclosed |